Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
67 studies found for:    kyprolis | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation
Condition: Lung Transplant Rejection
Intervention: Drug: Carfilzomib
2 Recruiting Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support
Condition: Multiple Myeloma
Interventions: Drug: Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan;   Drug: Carfilzomib/dexamethasone maintenance;   Drug: Observation without carfilzomib/dexamethasone maintenance
3 Recruiting B-Cell Targeted Carfilzomib Desensitization
Condition: Transplants and Implants
Intervention: Drug: Carfilzomib
4 Recruiting Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Condition: Neuroendocrine Cancer
Intervention: Drug: Carfilzomib
5 Recruiting Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone in Patients With Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Intervention: Drug: Carfilzomib
6 Recruiting Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
Conditions: Hematologic Malignancies;   Relapse;   Graft-Versus-Host Disease
Interventions: Drug: Carfilzomib;   Drug: Tacrolimus
7 Recruiting Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
Conditions: Non-Hodgkin Lymphoma;   Diffuse Large B-cell Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Peripheral T-cell Lymphoma
Interventions: Drug: Carfilzomib;   Drug: Belinostat
8 Recruiting Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib
9 Recruiting Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
Conditions: Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome
Interventions: Drug: carfilzomib;   Drug: romidepsin;   Other: laboratory biomarker analysis
10 Recruiting Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma
Conditions: Hodgkin Disease;   Lymphoma, Non-hodgkin
Interventions: Drug: Carfilzomib;   Drug: TGR-1202
11 Recruiting Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
Conditions: Relapsed Solid Tumors;   Refractory Solid Tumors;   Leukemias
Interventions: Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Etoposide
12 Recruiting Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
Condition: Relapsed or Refractory Multiple Myeloma
Interventions: Drug: Venetoclax;   Drug: Dexamethasone;   Drug: Carfilzomib
13 Recruiting Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Conditions: Small Cell Lung Carcinoma;   Non Small Cell Lung Carcinoma;   Irinotecan Sensitive Cancers
Interventions: Drug: Carfilzomib;   Drug: Irinotecan
14 Not yet recruiting Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Relapsed and/or Refractory Multiple Myeloma
Intervention: Drug: Carfilzomib, Thalidomide and Dexamethasone
15 Recruiting A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
16 Recruiting Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: pomalidomide;   Drug: carfilzomib;   Drug: dexamethasone
17 Recruiting Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients
Condition: Peripheral T Cell Lymphoma
Interventions: Drug: Romidepsin;   Drug: Carfilzomib
18 Recruiting Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bendamustine;   Drug: Carfilzomib;   Drug: Dexamethasone
19 Recruiting Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Prednisone;   Drug: Methylprednisolone
20 Recruiting Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Carfilzomib;   Drug: Dexamethasone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.